The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism

64Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: To describe the use of inhaled aerosolized prostacyclin (IAP) in a patient with life-threatening pulmonary hypertension secondary to pulmonary embolism and to discuss the possible use of inhaled prostacyclin in the management of pulmonary embolism. Design: Case report. Setting: Intensive care unit of a university teaching hospital. Patients: One patient with severe pulmonary hypertension secondary to acute-on-chronic pulmonary embolism. Interventions: Conventional medical management of massive pulmonary embolism and inhaled aerosolized prostacyclin (IAP). Measurements and results: Description of clinical course, haemodynamic data and gas exchange data. Conclusions: We describe a patient with massive pulmonary embolism for whom the addition of IAP to his therapy appeared to result in a transient improvement in pulmonary haemodynamics and gas exchange.

Cite

CITATION STYLE

APA

Webb, S. A. R., Stott, S., & Van Heerden, P. V. (1996). The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism. Intensive Care Medicine, 22(4), 353–355. https://doi.org/10.1007/BF01700458

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free